231 related articles for article (PubMed ID: 7585656)
41. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
42. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.
Buza N; Hui P
Genes Chromosomes Cancer; 2013 Dec; 52(12):1178-86. PubMed ID: 24123408
[TBL] [Abstract][Full Text] [Related]
43. HER-2/neu amplification and overexpression in endometrial carcinoma.
Rolitsky CD; Theil KS; McGaughy VR; Copeland LJ; Niemann TH
Int J Gynecol Pathol; 1999 Apr; 18(2):138-43. PubMed ID: 10202671
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.
Bigsby RM; Li AX; Bomalaski J; Stehman FB; Look KY; Sutton GP
Obstet Gynecol; 1992 Jan; 79(1):95-100. PubMed ID: 1345772
[TBL] [Abstract][Full Text] [Related]
45. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P
Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347
[TBL] [Abstract][Full Text] [Related]
47. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
48. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.
Coronado PJ; Vidart JA; Lopez-asenjo JA; Fasero M; Furio-bacete V; Magrina J; Escudero M
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):103-8. PubMed ID: 11516808
[TBL] [Abstract][Full Text] [Related]
49. Assessment of p53 and HER-2/neu genes status and protein products in oral squamous cell carcinomas.
Stoicănescu D; Andreescu N; Belengeanu A; Meszaros N; Cornianu M
Rom J Morphol Embryol; 2013; 54(4):1107-13. PubMed ID: 24399009
[TBL] [Abstract][Full Text] [Related]
50. HER 2/neu expression and gene amplification in colon cancer.
Nathanson DR; Culliford AT; Shia J; Chen B; D'Alessio M; Zeng ZS; Nash GM; Gerald W; Barany F; Paty PB
Int J Cancer; 2003 Jul; 105(6):796-802. PubMed ID: 12767065
[TBL] [Abstract][Full Text] [Related]
51. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
[TBL] [Abstract][Full Text] [Related]
52. [Amplification and overexpression of HER-2/neu in parotid gland salivary duct carcinoma. Immunohistochemical study and fluorescence in situ hybridization].
Skálová A; Stárek I; Vanĕcek T; Kucerová V; Plank L; Szépe P
Cesk Patol; 2002; 38 Suppl 1():27-34. PubMed ID: 12677894
[TBL] [Abstract][Full Text] [Related]
53. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
54. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
[TBL] [Abstract][Full Text] [Related]
55. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].
Scheer M; Prange W; Petmecky K; Schirmacher P; Zöller JE; Kübler AC
Mund Kiefer Gesichtschir; 2003 May; 7(3):138-45. PubMed ID: 12764679
[TBL] [Abstract][Full Text] [Related]
56. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
57. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients.
Kim HJ; Yoo TW; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MK; Chae SW; Sohn JH
Ann Oncol; 2007 May; 18(5):892-7. PubMed ID: 17322545
[TBL] [Abstract][Full Text] [Related]
58. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
Buchynska LG; Brieieva OV; Iurchenko NP
Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
[TBL] [Abstract][Full Text] [Related]
59. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
60. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.
Park DI; Kang MS; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Han WK; Kim H; Ryu SH; Sepulveda AR
Int J Colorectal Dis; 2007 May; 22(5):491-7. PubMed ID: 16947041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
